Although SL4 treatment activated the TGF-β signaling pathway in MDA-MB-231 cells, inhibition of TGF-β signaling by a specific inhibitor did not affect the SL4-induced G2/M phase arrest in breast cancer cells. The gene discussed is TGFB1; the disease is breast cancer.